These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28132823)

  • 1. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.
    Hagan A; Phillips GJ; Macfarlane WM; Lloyd AW; Czuczman P; Lewis AL
    Eur J Pharm Sci; 2017 Apr; 101():22-30. PubMed ID: 28132823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer.
    Duran R; Namur J; Pascale F; Czuczman P; Bascal Z; Kilpatrick H; Whomsley R; Ryan S; Lewis AL; Denys A
    Radiology; 2019 Dec; 293(3):695-703. PubMed ID: 31617791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.
    Hagan AE; Znati SA; Carter R; Westhorpe A; Macfarlane WM; Phillips GJ; Lloyd AW; Sharma RA; Lewis AL
    Anticancer Drugs; 2021 Oct; 32(9):897-908. PubMed ID: 33929994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™.
    Ashrafi K; Tang Y; Britton H; Domenge O; Blino D; Bushby AJ; Shuturminska K; den Hartog M; Radaelli A; Negussie AH; Mikhail AS; Woods DL; Krishnasamy V; Levy EB; Wood BJ; Willis SL; Dreher MR; Lewis AL
    J Control Release; 2017 Mar; 250():36-47. PubMed ID: 28188808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composition-property relationships for radiopaque composite materials: pre-loaded drug-eluting beads for transarterial chemoembolization.
    Kilcup N; Tonkopi E; Abraham RJ; Boyd D; Kehoe S
    J Biomater Appl; 2015 Jul; 30(1):93-103. PubMed ID: 25690386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer.
    Negussie AH; Mikhail AS; Owen JW; Hong N; Carlson CJ; Tang Y; Carrow KP; Mauda-Havakuk M; Lewis AL; Karanian JW; Pritchard WF; Wood BJ
    Sci Rep; 2022 Dec; 12(1):21886. PubMed ID: 36535979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vandetanib-eluting Radiopaque Beads:
    Denys A; Czuczman P; Grey D; Bascal Z; Whomsley R; Kilpatrick H; Lewis AL
    Theranostics; 2017; 7(8):2164-2176. PubMed ID: 28740542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of Radiopaque Drug-Eluting Beads for Transcatheter Chemoembolization.
    Johnson CG; Tang Y; Beck A; Dreher MR; Woods DL; Negussie AH; Donahue D; Levy EB; Willis SL; Lewis AL; Wood BJ; Sharma KV
    J Vasc Interv Radiol; 2016 Jan; 27(1):117-126.e3. PubMed ID: 26549370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance.
    Lewis AL; Willis SL; Dreher MR; Tang Y; Ashrafi K; Wood BJ; Levy EB; Sharma KV; Negussie AH; Mikhail AS
    Future Oncol; 2018 Nov; 14(26):2741-2760. PubMed ID: 29944007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
    Beaton L; Tregidgo HFJ; Znati SA; Forsyth S; Counsell N; Clarkson MJ; Bandula S; Chouhan M; Lowe HL; Thin MZ; Hague J; Sharma D; Pollok JM; Davidson BR; Raja J; Munneke G; Stuckey DJ; Bascal ZA; Wilde PE; Cooper S; Ryan S; Czuczman P; Boucher E; Hartley JA; Atkinson D; Lewis AL; Jansen M; Meyer T; Sharma RA
    J Vasc Interv Radiol; 2022 Sep; 33(9):1034-1044.e29. PubMed ID: 35526675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
    Hsu C; Yang TS; Huo TI; Hsieh RK; Yu CW; Hwang WS; Hsieh TY; Huang WT; Chao Y; Meng R; Cheng AL
    J Hepatol; 2012 May; 56(5):1097-1103. PubMed ID: 22245891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.
    Hagan A; Caine M; Press C; Macfarlane WM; Phillips G; Lloyd AW; Czuczman P; Kilpatrick H; Bascal Z; Tang Y; Garcia P; Lewis AL
    Eur J Pharm Sci; 2019 Aug; 136():104943. PubMed ID: 31152772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
    Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
    Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR and VEGFR as potential target for biological therapies in HCC cells.
    Giannelli G; Sgarra C; Porcelli L; Azzariti A; Antonaci S; Paradiso A
    Cancer Lett; 2008 Apr; 262(2):257-64. PubMed ID: 18248788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro Characterization of a Novel Type of Radiopaque Doxorubicin-Loaded Microsphere.
    Pan F; Schneider D; Ryschich E; Qian B; Vollherbst DF; Möhlenbruch MA; Jugold M; Eichwald V; Stenzel P; Pereira PL; Richter GM; Kauczor HU; Sommer CM; Do TD
    Cardiovasc Intervent Radiol; 2020 Apr; 43(4):636-647. PubMed ID: 31965224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience.
    Aliberti C; Carandina R; Sarti D; Pizzirani E; Ramondo G; Cillo U; Guadagni S; Fiorentini G
    Future Oncol; 2017 Oct; 13(25):2243-2252. PubMed ID: 29063780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization.
    Negussie AH; Dreher MR; Johnson CG; Tang Y; Lewis AL; Storm G; Sharma KV; Wood BJ
    J Mater Sci Mater Med; 2015 Jun; 26(6):198. PubMed ID: 26105830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art.
    Facciorusso A
    World J Gastroenterol; 2018 Jan; 24(2):161-169. PubMed ID: 29375202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.